WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

Similar documents
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV Drugs and the HIV Lifecycle

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

Antiretroviral Dosing in Renal Impairment

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

HIV medications HIV medication and schedule plan

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

Antiretrovial Crushable/Liquid Formulation Chart

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options

ANTIRETROVIRAL TREATMENTS (Part 1of

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications


Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO

HIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time

Nothing to disclose.

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

Nobel /03/28. HIV virus and infected CD4+ T cells

HIV Infection & AIDS in Low- and Middle-Income Countries

A Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs

JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet

BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search

Drug Treatment Program Update

ADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute

Addressing Pediatric Needs of the Most Neglected: next steps

Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.

Appropriate Use & Safety Edits

HIV Management Update 2015

Approach for the Newly Diagnosed HIV Positive Patient

treatment passport 1

Simplifying HIV Treatment Now and in the Future

Genotyping and Drug Resistance in Clinical Practice. Case Studies

continuing education for pharmacists

Adherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA)

The ART of Antiretroviral Therapy in Critically-ill Patients with HIV

MEDICATION RELATED ISSUES IN THE HIV PATIENT. LEONARD SOWAH, MBChB, MPH, FACP

FLORIDA!A MEDICAID' Better Health Care for all Floridians. May

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

October 26-28: Training Day 1

NON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days

Antiretroviral Pregnancy Registry

30 Years of HIV: An Update on Treatment Guidelines and Beyond

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist

FORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary

Selecting an Initial Antiretroviral Therapy (ART) Regimen

World AIDS Day Year-by-Year Milestones in HIV/AIDS. healthlibrary

ABRIDGED ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

P.I. Perspective. December 2008, Issue #47. Information, Inspiration and Advocacy for People Living with HIV/AIDS

Midwestern Underwriting Conference 2016

Medication Errors Focus on the HIV-Infected Patient

Industry Data Request

Human Immunodeficiency Virus Infection A Modern Day Epidemic

INDEX. indications...11 initiation of metabolic and morphologic complications

PROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY

ART and Prevention: What do we know?

HIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine

Matters of the HAART: An Update on Current Treatment Options for HIV

New Frontiers for Treatment Strategies for HIV Care

HIV Today: Examining the Latest Treatment Advances, Barriers to Care, and Pharmacists Implications

The New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010

Outline Epidemiology: Global and U.S. How are we doing in terms of goals of treatment? Updates in the fast moving field of HIV medicine EPIDEMIOLOGY

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018

Human Immunodeficiency Virus (HIV)

Objectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.

Criteria for Oral PrEP

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

May 2016 P & T Updates

The ART of Managing Drug-Drug Interactions in Patients with HIV

Fundamentals of Antiretroviral Therapy

The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease

Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course

Industry Request Integrase Inhibitors

The ABCs of ART: Designing Initial Antiretroviral Regimens for Beginners

Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos

HIV Update: Looking Forward, Where are we going? Outline

Comprehensive Guideline Summary

Quick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents

Jonathan Cohn MD Wayne State University July 24,

HIV in the Workplace

NATAPNATIONAL. HIV 102: Care & Treatment AIDS TREATMENT ADVOCACY PROJECT. Origins of HIV. Table of Contents. National AIDS Treatment Advocacy Project

HIV in the United States: At A Glance

Overview of HIV. LTC Paige Waterman

Recreational Drugs and HIV Antiretrovirals. A Guide to Interactions for Clinicians

Third Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf

OB/GYN CHART REVIEW DRAFT: NOT FOR DISTRTIBUTION

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION

HIV Treatment: New and Veteran Drugs Classes

Pharmacological considerations on the use of ARVs in pregnancy

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc

Transcription:

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 / 0 2 / 0 5 A4. DATE OF INTERVIEW: / / M D Y A5. INTERVIEWER S INITIALS: A6. TIME MODULE STARTED: : AM... 1 PM... 2 SECTION B. DOSAGE INFORMATION 1) In question B1, place a check mark next to each antiretroviral medication the participant has taken at least once since her (MONTH) study visit (from F22med, question B2a). Leave blank any antiretrovirals she has not taken at all since her (MONTH) study visit. 2) For each antiretroviral medication checked, ask the participant if she has taken [DRUG] in the past three days. If YES, i.e., the participant has taken this medication in the past three days: Circle 1 to indicate use in the past three days in column a. Record the total number of doses taken per day in column b. Record the total number of tablets or capsules or ml taken in column c. Some pills have different formulations (tablets or capsules or liqiud forms). Indicate the actual medication form/dose taken in column d. Skip to next checked medication on list. If NO, i.e., the participant has taken the medication since her last study visit but has not taken the medication in the past three days: Circle 2 to indicate no use in the past three days in column a. Skip to column e. Record the month and year when she stopped taking the medication in column e. Do NOT complete dosing information (columns b, c and d) for antiretrovirals the participant has not taken in the past three days. Skip to next checked medication on list. 3) In question B2, enter the number of boxes checked in question B1. PROMPT: INTERVIEWER READ TO THE PARTICIPANT: ENGLISH: A medication you have taken in the past three days includes any you have taken at least one time today, yesterday or the day before yesterday. SPANISH: Un medicamento que ha tomado en los últimos 3 días es un medicamento que haya tomado al menos una vez hoy, ayer o antes de ayer. Page 1 of 5

PROMPT: IF THE PARTICIPANT DOES NOT TAKE A MEDICATION EVERY DAY (E.G., TAKES IT ONLY EVERY OTHER DAY, OR ONCE PER WEEK), ENTER CODE 99 (FOR OTHER ) IN SUBQUESTION d. THEN ENTER THE ACTUAL DOSING SCHEDULE (E.G., 300 MG PER WEEK ) IN THE SPECIFY FIELD. SUBQUESTIONS b AND c SHOULD BE CODED AS -9. SEE QxQS FOR DETAILED EXAMPLES. START DSGs1 B1. Code Drug Name a. Past 3 days b. # c. # pills (or ml) / dose d. Formulation of drug e. Stop date Combination Medications 262 Atripla (Sustiva + Viread + Emtriva) 227 Combivir (AZT + 3TC) 254 Epzicom (3TC + abacabir) 240 Trizivir (abacavir + AZT + 3TC) 253 Truvada (tenofovir + FTC) 280 Complera (FTC + RPV + TDF) 287 Stribild (FTC + Viread + EVG + cobicistat) Entry Inhibitors 233 Fuzeon (T-20, enfuvirtide) 265 Selzentry (maraviroc) Nucleoside / Nucleotide RTIs (NRTIs) 239 Emtriva (emtricitabine, FTC) 204 Epivir (3TC, lamivudine) tablets tablets tablets tablets tablets tablets tablets ml tablets capsules or ml tablets or ml 600 mg efavirenz/ 200 mg emtricitabine/ 300 mg tenofovir tablet... 41 300mg AZT / 150mg 3TC tablet... 37 300mg lamividune/600mg abacavir tablet... 35 300mg abacavir/300mg AZT/ 150mg 3TC tablet... 36 300mg tenofovir/200mg FTC tablet... 38 200mg FTC/25mg RPV/300mg TDF tablet... 50 200mg FTC/300mg Viread/150mg EVG/150 mg cobicistat tablet.. 52 90mg/ml... 15 300 mg tablet... 27 200mg capsule... 21 Liquid form (10 mg/ml)... 4 300 mg tablet...27 Liquid form (10 mg/ml)...4 Page 2 of 5

B1. Code Drug Name a. Past 3 days b. # c. # pills (or ml) / dose d. Formulation of drug e. Stop date tablets or 300 mg tablet...27 Retrovir (AZT, ZDV, 092 capsules or ml 100 mg capsule... 16 zidovudine) Liquid form (50 mg/5 ml)...13 147 Videx or Videx EC (didanosine, ddi) 234 Viread (tenofovir) 159 Zerit (d4t, stavudine) 218 Ziagen (abacavir, ABC) Integrase Inhibitors 264 Isentress (raltegravir, MK 0518) 286 Tivicay (dolutegravir) Non-nucleoside RTIs (NNRTIs) 194 Rescriptor (delavirdine) capsules or tablets or ml tablets or g capsules or ml tablets or ml tablets tablets tablets 400 mg capsule... 29 250 mg capsule... 25 125 mg capsule... 18 50 mg tablet... 12 Liquid form (20 mg/ml)... 7 Liquid form (10 mg/ml)... 4 150mg tablet... 20 200mg tablet... 24 250mg tablet... 26 300mg tablet... 27 Oral powder (40 mg/g)... 51 40 mg capsule... 10 30 mg capsule... 9 20 mg capsule... 6 15 mg capsule... 5 Liquid form (1 mg/ml)... 3 300 mg tablet... 27 Liquid form (20 mg/ml)... 7 25mg tablet... 8 100mg tablet... 17 400 mg tablet... 43 50mg tablet... 12 Page 3 of 5

B1. Code Drug Name a. Past 3 days b. # c. # pills (or ml) / dose d. Formulation of drug e. Stop date 220 Sustiva (efavirenz) 191 Viramune (nevirapine) 255 Intelence (etravirine, TMC 125) 276 Edurant (rilpivirine, TMC 278) Protease Inhibitors (PIs) 238 Aptivus (tipranavir) 212 Crixivan (indinavir) 210 Invirase (saquinavir) 217 Kaletra (lopinavir + ritonavir) 249 Lexiva (fosamprenavir) 211 Norvir (ritonavir) tablets or capsules tablets or ml tablets tablets capsules or ml capsules capsules or tablets tablets or ml tablets or ml capsules or tablets or ml 600 mg tablet... 31 50 mg capsule... 11 400 mg tablet (XR form)... 43 Liquid form (50 mg/5 ml)... 13 250mg capsule... 25 Liquid form (100 mg/ml)... 45 400 mg capsule... 29 100 mg capsule... 16 200 mg Invirase capsule... 23 500 mg Invirase tablet... 30 Tablet form (200mg lopinavir/50mg ritonavir)... 40 (100mg lopinavir/25mg ritonavir)... 46 Liquid form... 39 (80mg/ml lopinavir / 20mg/ml ritonavir) 700 mg tablet... 48 Liquid form (50 mg/ml)... 47 100 mg capsule... 16 Liquid form (80 mg/ml)... 14 Page 4 of 5

B1. Code Drug Name a. Past 3 days b. # c. # pills (or ml) / dose d. Formulation of drug e. Stop date 256 Prezista (TMC-114, darunavir) 243 Reyataz (atazanavir) 216 Viracept (nelfinavir) tablets or ml capsules tablets or g 75 mg tablet... 44 150 mg tablet... 20 300 mg tablet... 27 400 mg tablet... 43 600 mg tablet... 31 800 mg tablet... 53 Liquid form (100 mg/ml)... 45 300 mg capsule...42 150 mg capsule... 19 100 mg capsule...16 625 mg tablet...32 (usually 2 tabs 2x/day) 250 mg tablet... 26 (usually 5 tabs 2x/day) Oral powder (50 mg/g)...49 B1. Drug Code and Name a. Past 3 days b. # c. # pills (or ml) / dose d. Formulation of drug e. Stop date Other Antiretrovirals (from Drug List 1) Other... 99 Specify drug code & name: YES... 1 (b,c,d) Specify dose, size and form: Specify drug code & name: YES... 1 (b,c,d) Other... 99 Specify dose, size and form: END DSGs1 B2. ENTER THE TOTAL NUMBER OF ANTIRETROVIRAL MEDICATIONS CHECKED IN QUESTION B1: B3. TIME MODULE ENDED: : AM... 1 PM... 2 PROMPT: COMPLETE A DRUG FORM 1 FOR EVERY ANTIRETROVIRAL MEDICATION THE PARTICIPANT HAS TAKEN IN THE PAST 3 DAYS, I.E., FOR EVERY MEDICATION WITH RESPONSE IN COLUMN a = 1. Page 5 of 5